Check category
The company signed the agreement on the investment to you
- Categories:Company news
- Author:Chun Ye
- Origin:
- Time of issue:2021-12-02
- Views:0
(Summary description)On December 2nd, Hu Jian, general manager of the company, and Wu Mingming, general manager of Shanghai Yujun Biotechnology Development Co., Ltd. signed the investment agreement, marking the strategic
The company signed the agreement on the investment to you
(Summary description)On December 2nd, Hu Jian, general manager of the company, and Wu Mingming, general manager of Shanghai Yujun Biotechnology Development Co., Ltd. signed the investment agreement, marking the strategic
- Categories:Company news
- Author:Chun Ye
- Origin:
- Time of issue:2021-12-02
- Views:0
Information
On December 2nd, Hu Jian, general manager of the company, and Wu Mingming, general manager of Shanghai Yujun Biotechnology Development Co., Ltd. signed the investment agreement, marking the strategic cooperation between the two sides. This cooperation will help both sides give full play to the advantages of their respective platforms and carry out in-depth cooperation in multiple business areas.
Shanghai Yujun Biotechnology Development Co., Ltd. is a CRO/CDMO company serving the field of innovative drugs and new materials, focusing on technology accumulation and breakthrough of main products for a long time. Yujun bio's current R&D center is located in Minhang, Shanghai, with a new 3,600-square-meter first phase and a 6,700-square-meter second phase in Lingang, Shanghai. The first phase is expected to be put into operation in early 2022, with additional r&d centers in Xi 'an and Wuhan in preparation. Yujun biological is good at many special technologies, such as alkylation technology, ultra-low temperature reaction, ozone reaction, etc., and also good at new continuous flow reaction forms, and has rich experience in the application of metal catalysis and enzyme catalysis technology, has strong competitiveness in the industry.
The contrast agent preparation products are on the market and entered the national collective procurement, marking the landing of the integrated strategy of "intermediate-raw material-preparation" of our company, which is more mature and stable in the development of the subdivision of contrast agent. The opening of this cooperation also marks our company's development and exploration in the new business section, injecting fresh vitality into the sustainable development of the company's business.
Scan the QR code to read on your phone
Product
News
Research
Responsibility
Wap
Copyright © 2019 Zhejiang Starry Pharmaceutical Co., Ltd. All Rights Reserved. 浙ICP备18046522号